Answers are grounded in this paper and cite their sources.
Background: Type 2 Diabetes Mellitus (T2DM) accounts for approximately 90% of diabetes cases and is projected to rise to 783.2 million by 2045. This escalating prevalence underscores the urgent need for novel therapeutic agents with improved efficacy and minimal side effects. Berberis aristata DC., commonly known as Daruharidra, or Indian Barberry, has been extensively referenced in Ayurvedic texts for its use in managing diabetes. Aim: The present study aimed to employ a network pharmacology and molecular docking approach to identify potential molecular targets, pathways, and mechanisms underlying the anti-diabetic effects of B. aristata. Methods: Bioactive compounds of B. aristata were retrieved from the IMPPAT 2.0 database and screened for drug-likeness. Network pharmacology, protein-protein interaction analyses, functional enrichment, and pathway analyses were conducted using tools such as Cytoscape, Metascape and STRING. Molecular docking was performed using the Glide module from Schrodinger Suite 40. Results: The study identified six bioactive compounds, 282 target genes, and 26 disease terms associated with T2DM and its major complications. Key target genes were found to be linked to conditions such as fatty liver disease, diabetes mellitus, hypercholesterolemia, and hyperlipidaemia. Functional enrichment analysis highlighted involvement of target genes in critical pathways, including lipid metabolism, responses to hormones like insulin, glucagon, and incretins, cellular lipid responses, oxidative stress, and the AGE-RAGE signalling pathway. The docking study revealed that Berberine, Rutin, Jatrorrhizine, Palmatine and Quercetin have a high affinity with 6THA (Human sugar transporter 1 protein), 4NO7 (Human Glucokinase) and 7WSM (Human sugar transporter 4 protein). Conclusion: This study elucidates the anti-diabetic potential of B. aristata and demonstrates its ability to modulate multiple target genes and pathways central to metabolic dysfunction and the progression of T2DM, providing a scientific basis for its therapeutic applications in type 2 diabetes management. Major Findings: The study reveals that B. aristata targets are involved in key T2DM pathways, including insulin signalling, lipid transport, and glucose homeostasis. Target regulatory hubs highlight their role in modulating insulin resistance and β-cell dysfunction. Its major phytoconstituents exhibited strong binding affinity toward key glucose regulatory proteins (GLUT1, GLUT4, and GCK).
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: